CORC

在结果中检索

CORC

浏览/检索结果: 共24条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
BRCANet: A deep hybrid network in predicting BRCA1/2 gene mutation of breast cancer with dynamic contrast-enhanced breast MRI. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Cao, Wen-Ming;  Wang, Xiaojia;  Liu, Jian;  Wang, Lili;  Zhang, Xiaodong
收藏  |  浏览/下载：13/0  |  提交时间：2022/12/23
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：35/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05
EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-B and Erk1/2 pathways 期刊论文
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 卷号: Vol.38
作者:  Lin, Cheng;  Zong, Jingfeng;  Lin, Wansong;  Wang, Minghui;  Xu, Yuanji
收藏  |  浏览/下载：21/0  |  提交时间：2019/12/13
Correction to: EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways. 期刊论文
Journal of Experimental & Clinical Cancer Research, 2019, 卷号: Vol.38 No.1
作者:  Lin, Cheng;  Zong, Jingfeng;  Lin, Wansong;  Wang, Minghui;  Xu, Yuanji
收藏  |  浏览/下载：22/0  |  提交时间：2019/12/13
Correction to: EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways. 期刊论文
Journal of experimental & clinical cancer research, 2019, 卷号: Vol.38 No.1, 页码: 34
作者:  Cheng Lin;  Jingfeng Zong;  Wansong Lin;  Minghui Wang;  Yuanji Xu
收藏  |  浏览/下载：33/0  |  提交时间：2019/12/13

©版权所有 ©2017 CSpace - Powered by CSpace